Small Cell Lung Carcinoma
Conditions
Keywords
ES-SCLC, Concurrent Radiochemotherapy, Adebrelimab
Brief summary
Patients with extensive-stage small-cell lung cancer (ES-SCLC) have poor prognosis, with limited treatment options. Chemo-immunotherapy is the standard 1st-line therapy for patients with ES-SCLC.When 4 cycles of etoposide+carboplatin (EC) or etoposide+cisplatin(EP) chemotherapy combined with PD-L1 inhibitor are effective, guidelines recommend additional thoracic radiotherapy. In this study, the investigators bring radiotherapy forward, which means that after 2 cycles of EC chemotherapy plus Adebrelimab, participants with response（PR/CR/SD）will receive concurrent radiotherapy and 2 cycles of EC chemotherapy plus Adebrelimab, then maintenance therapy with Adebrelimab （Q3W）. The purpose of this study is to explore the safety and efficacy of Adebrelimab combined with concurrent chemoradiotherapy in untreated participants with extensive-stage small cell lung cancer.
Detailed description
Participants receive EC chemotherapy combined with Adebrelimab for 2 cycles, and the efficacy will be evaluated. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy combined with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy + Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Interventions
DRUGAdebrelimab
Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
RADIATIONRadiation Therapy
Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
DRUGetoposide, carboplatin(EC)
Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Sponsors
Huazhong University of Science and Technology
Henan Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-75 years; 2. Histologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \[VALG\] staging system) ; 3. Must sign a written informed consent form prior to any study specific procedures; 4. No prior treatment for ES-SCLC; 5. No more than 5 lesions (including metastases),and at least one measurable lesion that meets RECIST 1.1 evaluation criteria; 6. Life expectancy more than 3 months; 7. ECOG PS 0-1
Exclusion criteria
1. Previous treatment with radiochemotherapy for limited-stage small cell lung cancer; 2. Subjects who previously received systemic antitumor or Immune checkpoint inhibitor therapy ; 3. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; 4. Active brain metastases, Leptomeningeal metastasis(untreated central nervous system (CNS) metastases unless asymptomatic and lesion size\<1cm; 5. Patients with spinal cord compression; 6. Patients with multiple liver metastases(except isolated lesion and lesion size\<2cm); 7. Uncontrollable third cavity effusion (e.g. a large amount of pleural effusion, ascites, or pericardial effusion, etc.) requiring repeated drainage, which was judged by the investigator to be unsuitable for study; 8. The investigator judges that there are any patients who endanger the patient's safety, interfere with the study assessment, and have poor compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 6-m PFS rate | 6 months | 6-m PFS rate is defined as the percentage of participants whose disease is still progression-free at the 6th month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 24 months. | Objective response rate is defined as the proportion of subjects who have a CR or a PR |
| PFS | From date of the first treatment to the first documented disease progression, assessed up to 24 months | Progression-free survival is defined as the time from the first treatment to the first documented disease progression |
| OS | From date of the first treatment to death due to any cause, assessed up to 24 months | Overall survival is defined as the time from the first treatment to death due to any cause. |
| 12-m PFS rate | 12 months | 12-m PFS rate is defined as the percentage of participants whose disease is still progression-free at the 12th month |
| AEs | up to 24 months | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
Countries
China
Contacts
Primary ContactQimig Wang, Doctor
Outcome results
None listed